LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Strona główna・Stock List・Geron Corp

Geron Corp

Closed

SectorHealthcare

1.67 0.6

Buy Sell

Overview

Share price change

24h

Current

Min

1.63

Max

1.67

Key metrics
By Trading Economics
Income	-2.1M -18M
Sales	-1.8M 47M
EPS	-0.03
Profit margin	-39.02
Employees	229
EBITDA	-2.1M -9.7M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+96.97% upside

Dividends
By Dow Jones
Next Earnings	6 maj 2026

Market Stats
By TradingEconomics
Market Cap	364M 1.1B
Previous open	1.07
Previous close	1.67

Geron Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 lut 2026, 23:53 UTC

Hot Stocks

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 lut 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

28 lut 2026, 21:36 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 lut 2026, 15:20 UTC

Earnings

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28 lut 2026, 14:43 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 lut 2026, 14:38 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28 lut 2026, 13:47 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 lut 2026, 13:44 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28 lut 2026, 13:14 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 lut 2026, 02:32 UTC

Earnings

Acquisitions, Mergers, Takeovers

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28 lut 2026, 02:00 UTC

Acquisitions, Mergers, Takeovers

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28 lut 2026, 02:00 UTC

Acquisitions, Mergers, Takeovers

Six Months, 9 Offers and $81 Billion. How -2-

28 lut 2026, 00:01 UTC

Acquisitions, Mergers, Takeovers

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27 lut 2026, 23:46 UTC

Acquisitions, Mergers, Takeovers

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 lut 2026, 23:33 UTC

Acquisitions, Mergers, Takeovers

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 lut 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

27 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 lut 2026, 21:30 UTC

Earnings

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 lut 2026, 21:30 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 lut 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 lut 2026, 21:17 UTC

Earnings

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 lut 2026, 21:10 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 lut 2026, 21:09 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 lut 2026, 21:00 UTC

Earnings

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 lut 2026, 20:31 UTC

Acquisitions, Mergers, Takeovers

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 lut 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 lut 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 lut 2026, 20:12 UTC

Market Talk

Nike Seen With Further Challenges in China -- Market Talk

27 lut 2026, 19:44 UTC

Market Talk

Gold Caps Historic Month -- Market Talk

27 lut 2026, 19:39 UTC

Earnings

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

Peer Comparison

Price change

Geron Corp Forecast

Price Target

By TipRanks

96.97% upside

12 Months Forecast

Average 3.25 USD 96.97%

High 5 USD

Low 1 USD

Based on 5 Wall Street analysts offering 12 month price targets forGeron Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Geron Corp - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.